Rezolute (RZLT) Corporate presentation summary

Company overview and strategy

• Focuses on ultra-rare diseases, specifically refractory hypoglycemia caused by hyperinsulinism (HI), with a lead antibody therapy, ersodetug (RZ358).

• Two late-stage clinical programs target congenital and tumor-induced HI.

• Expanded access program and clinical trials provide evidence of efficacy and safety.

• Management team has experience from early development to commercialization.

• $120 million in cash provides runway to mid-2028.

Clinical programs and milestones

• Ersodetug is in late-stage trials for congenital HI and tumor HI, with topline data expected in 2H 2026.

• Additional pipeline opportunities exist for GI-surgery-induced hypoglycemia.

• FDA and EMA have granted multiple designations, including Breakthrough Therapy and Orphan Drug status.

• Phase 3 sunRIZE study completed for congenital HI; open-label extension ongoing.

• Phase 3 upLIFT study for tumor HI is ongoing, with interim results favorable and topline data expected in 2H 2026.

Disease background and unmet need

• Congenital HI is the most common cause of persistent hypoglycemia in infants, with high risk of neurological damage and no approved chronic therapy for all genetic forms.

• Tumor HI includes insulinomas and non-islet cell tumors, both with severe hypoglycemia and limited treatment options.

• Current standard of care (e.g., diazoxide) is ineffective or poorly tolerated in a significant portion of patients.

• High unmet need persists for both congenital and tumor HI populations.